We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Avastin Shot Down by ODAC for Breast Cancer on Split Vote
Avastin Shot Down by ODAC for Breast Cancer on Split Vote
December 7, 2007
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 5–4 recommending that the data in Genentech’s supplemental biologics license application (sBLA) for the use of Avastin in the treatment of breast cancer were not sufficient to establish a net clinical benefit.